In the same year the ITC also noted on their endeavours to the flow syntheses of two lead compounds claimed before by AstraZeneca. The 1st just one specifics the stream synthesis of a strong 5HT1B antagonist (28) that was assembled via a five step continual synthesis which include a SNAr reaction, heterogeneous hydrogenation, Michael addition–cyc